Down a dusty farm track in Chilean wine country, behind a wooden gate wrapped in chains, forestry experts are nursing a plantation of saplings whose bark holds the promise of potent vaccines.
Quillay trees, technically known as Quillaja saponaria, are rare evergreens native to Chile that have long been used by the indigenous Mapuche people to make soap and medicine. In the past few years, they have also been used to make a highly successful vaccine against shingles and the world’s first malaria vaccine, as well as foaming agents for products in the food, beverage and mining industries.
Now two saponin molecules, made from the bark of branches pruned from older trees in Chile’s forests, are being used for a COVID-19 vaccine developed by drugmaker Novavax Inc. The chemicals are used to make an adjuvant that reportedly boosts the immune system.
Over the next two years, Maryland-based Novavax plans to produce billions of doses of the vaccine, mostly for low and middle-income countries, which would make it one of the largest COVID-19 vaccine suppliers in the world.
With no reliable data on how many healthy quillay trees are left in Chile, experts and industry officials are divided on how quickly the supply of older trees could be depleted by rising demand.
However, nearly everyone agrees that industries relying on quillay extracts would at some point need to switch to trees grown in plantations or a lab-grown alternative.
A Reuters analysis of export data from trade data provider ImportGenius showed that the supply of older trees is under increasing pressure. Exports of quillay products more than tripled to more than 3,600 tonnes per year in the decade before the COVID-19 pandemic.
Ricardo San Martin, who developed the pruning and extraction process that created the modern quillay industry, said that producers must immediately work toward making quillay products from younger, plantation-grown trees.
“My estimate four years ago was that we were heading toward the sustainability limit,” he said.
San Martin said he has toiled through the pandemic in the basement of his oceanfront cabin in Sea Ranch, California, to refine a process that could help produce saponins from leaves and twigs to maximize the yield.
“I am working as though this needs to be done yesterday,” said San Martin, who is also sponsoring a project in which drones would count quillay trees in remote and hard-to-access forests, to determine how many are left.
Quillay producers and their customers say the harvest can continue for now without decimating the supply of older trees.
“We continue to monitor the situation in Chile, in close collaboration with our supplier, but at this time we are confident in our supply,” Novavax said in a statement.
The company also said it was confident that uses such as “life-saving vaccines will be prioritized.”
The desert-plant extract company Desert King International Ltd, which runs the Casablanca plantation, is Novavax’s sole supplier of quillay extracts and Chile’s largest quillay exporter by far.
Desert King general manager of Chile and natural response Andres Gonzalez said it is set to produce enough quillay extract from older trees to make up to 4.4 billion vaccine doses next year.
With new supplies from privately owned native forests, they have enough raw material to meet demand for the rest of this year and part of the next, he said.
Gonzalez said the company, where San Martin is a consultant, has built a new production plant and has the capacity to supply other interested pharmaceutical firms — all without harming the forests.
However, he said that “at some point these native forests will come to an end.”
“We want to start having very productive plantations, and we are working on that,” he said.
A relatively small volume of quillay extract is required to make vaccines — just under 1mg per dose — but the supply is stretched by the demand from other industries. Quillay products are used, for instance, as a natural additive in animal feed, a biopesticide and an agent to reduce pollution in mining.
Individual quillay trees grow outside of Chile, but Chile is the only country where mature quillay is harvested from forests in large quantities.
Novavax’s adjuvant, known as Matrix-M, contains two key saponin molecules. One of those, called QS-21, is more difficult to access because it is found mainly in trees that are at least 10 years old.
Among major pharmaceutical companies, only GlaxoSmithKline PLC and Novavax have bet heavily on QS-21, a relatively new pharmaceutical ingredient.
GSK’s highly successful vaccine against shingles, Shingrix, and several other promising experimental vaccines contain QS-21 supplied by Desert King.
In a statement, GSK said it has “no specific challenges relating to sustainable supply” of QS-21.
The quillay-based adjuvant used in Shingrix is also part of the world’s first malaria vaccine, Mosquirix.
The WHO on Wednesday said that it should be widely given to African children, marking what could be a major advance against malaria.
No other COVID-19 vaccine manufacturers are relying on quillay bark extracts. Some drugmakers are developing synthetic alternatives, but these could be years from regulatory approval. Switching out the ingredients in any existing vaccine would require new clinical studies to prove the product is safe and effective.
The Massachusetts-based pharmaceutical company Agenus stopped selling bark-derived QS-21 several years ago to focus full-time on trying to grow it from quillay plant cells in a laboratory.
“The shortage of QS-21 has been an issue for a while,” Agenus vice president of strategic initiatives and growth exploration Jason Paragas said. “We saw it before COVID, and we made the hard decision that we had to change.”
Paragas said it is too soon to say when an alternative could be ready.
Entrepreneur Gaston Salinas said his Davis, California-based start-up Botanical Solution Inc can already produce QS-21 from quillay tissue starting with seeds in the lab, and aims to eventually produce the chemical on a large scale to supply pharmaceutical companies.
“You cannot afford to over-exploit the native Chilean forest because of a desire to develop modern vaccines. You need to find other ways to develop your products, even if it’s something so important,” he said.
Inside the gate of the carefully guarded Desert King plantation, gardeners carefully tend to the young trees using fertilizers and bountiful supplies of water. They were cloned from full-grown cousins whose dusty gray bark is especially rich in saponins.
If all goes well, the plantation could be producing for one customer in two to three years, Desert King business development manager Damian Hiley said.
He declined to name the company.
Desert King has its eye on future vaccines, some already in the works.
In early 2020, for instance, GSK licensed an experimental tuberculosis vaccine that contains GSK’s QS-21-based adjuvant to the Bill and Melinda Gates Medical Research Institute. It showed promising results in a mid-stage trial.
In April, researchers at Oxford University announced that a new malaria vaccine containing Novavax’s Matrix-M adjuvant appeared to be highly effective in a trial involving 450 children in Burkina Faso.
Gustavo Cruz, a researcher at the University of Chile who worked with San Martin to industrialize production of quillay, said he generally trusts quillay producers to manage supply and demand. He is more worried about other threats — specifically drought and fire.
“The trees do eventually regrow, but there comes a time when they don’t anymore,” he said.
SELF-SUFFICIENCY: Alibaba is one of a number of Chinese firms that has answered Beijing’s call to invest in the development of cutting-edge technologies Alibaba Group Holding Ltd (阿里巴巴) yesterday unveiled a new server chip that is based on advanced 5-nanometer technology, marking a milestone in China’s pursuit of semiconductor self-sufficiency. The Chinese tech giant’s newest chip is based on micro-architecture provided by the SoftBank Group Corp-owned Arm Ltd, it said. Alibaba, which is holding its annual cloud summit in Hangzhou, China, said that the chip is to be used in its own data centers in the “near future” and would not, for the time being, be sold commercially. “Customizing our own server chips is consistent with our ongoing efforts toward boosting our computing capabilities with better
‘SHORT-TERM ECONOMIC PAIN’: A military takeover would only temporarily weigh on wafer production on both sides of the Taiwan Strait, IC Insights said Taiwan has more chip manufacturing capacity than any other economy in the world, US-based market information advisory firm IC Insights said in a research paper last week, cautioning that the nation’s strength could prompt China to attempt to take over Taiwan. Taiwan commanded 21.4 percent of global installed IC capacity, ahead of South Korea’s 20.4 percent, Japan’s 15.8 percent and China’s 15.3 percent, North America’s 12.6 percent and Europe’s 5.7 percent, IC Insights said. Taiwan is one of two countries that uses 10-nanometer technology or better to produce wafers, holding 62.8 percent of global capacity, with South Korea holding the remaining 37.2
AGGRESSIVE STEP: With the new processors, Apple is aiming at the high-end chips Intel has provided for the MacBook Pro and other top-end Macs for about 15 years Apple Inc on Monday took the most aggressive step yet to strip Intel Corp chips from its computers, announcing more powerful homegrown Mac processors alongside a total revamp of its MacBook Pro laptop computers. The company showcased the chips at an event called “Unleashed,” which also included its latest audio products. The new components, called the M1 Pro and M1 Max chips, are 70 percent faster than its M1 predecessors, Apple said. It also unveiled a redesigned MacBook Pro, adding larger screens, MagSafe charging and better resolution. With the new processors and devices, Apple is aiming squarely at the high-end chips that Intel has
PRICE SPREAD: Oil trading under the Brent futures contract is giving the US a hefty edge in pricing, increasing the rush to secure cheap fuel as winter approaches Asian demand for US oil is rising as the energy crisis boosts prices for other crudes that are priced against the global Brent futures contract. China and other Asian buyers have been snapping up supertankers of US oil for delivery next month and seeking more for December, some traders have said. Most buyers are seeking US grades that had recently slumped to the lowest levels in more than a year, with an added incentive after Beijing awarded millions of tonnes of crude oil import quotas. A wide spread between Brent and West Texas Intermediate (WTI) oil futures is accommodating higher US crude